ISPO

Prognostic Markers

Enzyme assay of alpha-n-acetylgalactosaminidase on ehrlich tumor bearing mice and clinical cancer patients

Y Koga MD, VR Naraparaju PhD, N Yamamoto PhD

Proliferation potential and apoptosis in the prognosis of neuroepithelial tumors

P Cavalla MD, D Schiffer MD

Prognostic value of collagen IV immunostaining in transitional cell carcinomas of the urinary bladder

A Borda MD, N Berger MD, F Chapuis MD, MH Grillet MD, F Piaton MD

Major salivary gland lesions: correlation of MR imaging findings with flow cytometric DNA analysis and prognosis

S Takashima MD, S Sone MD, Y Maruyama MD, M Hasegawa MD, L Feng MD

Degree of thyrotropin suppression as a prognostic determinant in thyroid cancer

P Pujol MD PhD, JP Daures MD PHD, N Nsakala MD, L Baldet MD, J Bringer MD, C Jaffiol MD

Cytokeratin markers in non-small cell ling cancer and malignant mesothelioma

B Nisman MD PhD, J Lafair MD, N Heching MD, V Barak PhD

Diagnosis of pleural malignant mesothelioma by immunohistochemistry and electron microscopy; analysis of p53 and ki67 as prognostic indicators

V Caputo MD, F Radice MD, L Santambrogio MD, L Matturri MD

Biological markers predictive prognostic power in 836 invasive breast cancers

P Querzoli MD, G Albonico MD, S Ferretti MD, R Rinaldi MD, I Nenci MD

Biophenotypes of 66 in situ breast cancers

G Albonico MD, P Querzoli MD, S Ferretti MD, R Rinaldi MD, I Nenci MD

Human breast cancer: loss of heterozygosity and hormonal phenotype

L Roncuzzi PhD, L Lenzi PhD, D Amadori MD, A Gasperi-Campani MD PhD

Estradiol metabolism, cyplal polymorphism, and breast cancer risk

E Taioli, HL Bradlow, MP Osborne, D Sepkovic, S Garbers, J Trachman, S Mehl, SJ Garte

The significance of serum HGF level as a prognostic indicator in breast cancer patients

M Toi, T Taniguchi, T Ueno, Y Yamamoto, T Tominaga

Non-specific labeled cells that simulate bone marrow tumor cells in metastasis free breast cancer patients

M Lagrange PhD, JM Ferrero MD, JL Lagrange MD, C Bayle MD, JC Machiavello MD, J Monticelli MD, M Namer MD, C Bourcier, J Gioanni PhD, A Thyss MD, M Schneider MD

Prognostic value of serum CA 15-3 and carcinoembryonic (CEA) antigens in postmenopausal breast cancer patients: a comparative preliminary study

J Wojtacki MD, A Dziewulska-Bokiniec MD PhD, G Rolka-Stempniewicz MD

Relationship between estrogen receptor (ER) expression and prognostic factors in postmenopausal breast cancer women

DM Kowalski MD, M Suszko MD, W Hajdukiewicz MD

A role of nm23 expression in gastric carcinoma: relations of the expression to clinicopathology and proliferative activity of carcinoma cells

T Nakamura MD, Y Tabuchi MD PhD, M Ohno MD, Y Saitoh MD PhD

A cytometric study of small liver cell dysplasia

L Matturri MD, B Biondo ScD, AM Lavezzi MD

Biomarkers of plutonium deposition in the liver

R Weller DVM, J Park DVM, G Dagle DVM PhD, C Watson, R Buschbom

Angiographic evaluation in curative resectability and prognosis of carcinoma of the pancreas

M Mori MD, H Tsuge MD, H Mimura MD, Y Shima MD, N Tamaka MD

Plasma levels of thioredoxin in patients with pancreatic tumor

H Nakamura MD, S Ueda MD, A Takabayashi MD, G Ohshio MD, M Imamura MD, J Yodoi MD, Y Yamaoka MD

Breast cancer prognostic significance of some modified urinary nucleosides

AJ Sasco MD PhD, F Rey MD, C Reynaud PhD, A Nivelean PhD

Deficiency of GST genes and risk of bladder cancer and schistosomiasis

A Hirvonen PhD, MA Watson MSc, DA Bell PhD, HM Mostafa MD, WA Anwar MD

Differential expression of Ki-67 and agnors in meningiomas

M Benchaib MD, MC Barioz, N Pirodon, B Pasquier MD, E Piaton MD

CD34 antigen expression in adult acute myeloid leukemias may have a prognostic significance

F Stagno MD, RR Cacciola MD, P Fiumara MD, P Guglielmo MD, E Cacciola MD

Malignant fibrous histiocytoma of bone: prognostic value of PCNA, Ki-67, p53 expression and its clinicopathologic correlation

A Parafioriti MD, E Armiraglio MD, PA Daolio MD, A Lavezzi MD, L Matturri MD

Determination of the expression of deoxynucleoside kinases as a prognostic marker for cancer therapy

S Eriksson MD PhD

C-myc and k-ras amplififcation in renal clear cell adenocarcinoma

I Ember, I Kiss, J Sandor, L Kozma, SZ Szakall, A Nagy